Conditions: Congestive Heart Failure
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 4128
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Irbesartan intervention 2: Placebo
Intervention descriptions: intervention 1: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years intervention 2: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

Protocol document: